- 标题
- 摘要
- 关键词
- 实验方案
- 产品
-
Diode-pumped Kerr-lens mode-locked Ti: sapphire laser with broad wavelength tunability
摘要： The aim of this study was to establish and validate a rapid, selective and reliable ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) for simultaneous quantitations of morin and morusin, and to investigate their pharmacokinetics difference between normal and diabetic rats after oral administration. Plasma samples were pretreated via protein precipitation with acetonitrile. Genkwanin was used as internal standard (IS). Analytes and IS were separated on a Thermo Hypersil Gold C18 column (50 × 4.6 mm, 3 μm) using gradient elution. The mobile phase consisted of acetonitrile and 0.1% formic acid in water at a flow rate of 0.5 mL/min. Mass spectrometry detection was carried out by means of negative electrospray ionization source and multipe‐reaction monitoring mode. The transitions of m/z 300.9 → 151.2 for morin, m/z 419.2 → 297.1 for morusin and m/z 283.1 → 268.2 for IS were chosen for quantification. Calibration curves were linear in the range of 1.01–504.2 ng/mL (r2 ≥ 0.99) for morin and 1.02–522.3 ng/mL (r2 ≥ 0.99) for morusin. The lower limit of quantification was 1.02 ng/mL for morin and 1.05 ng/mL for morusin. The extraction recovery was >85.1% for each analyte. No obvious matrix effect was observed under the present UPLC–MS/MS conditions during all of the bioanalysis. The stability study demonstrated that morin and morusin remained stable during the whole analytical procedure. The method was successfully applied to support the pharmacokinetic comparisons of morin and morusin between normal and diabetic rats.
关键词： UPLC–MS/MS,pharmacokinetic,diabetic rats,morusin,morin
更新于2025-09-19 17:13:59
-
7.5: Research on Quantum Dots and Phosphor Blend Backlight Module
摘要： DP‐VPA is a phospholipid prodrug of valproic acid (VPA) that is developed as a potential treatment for epilepsy. To characterize the pharmacokinetics and excretion of DP‐VPA, four reliable ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) methods were validated for quantitation of DP‐VPA and its metabolite, VPA, in human plasma, urine, and feces. Protein precipitation and solid‐phase extraction (SPE) were used for extraction of C16, C18 homologs of DP‐VPA and VPA, respectively, from plasma. Urine and fecal homogenate involving the three analytes were efficiently prepared by methanol precipitation. The determinations of C16 DP‐VPA, C18 DP‐VPA, and VPA were performed using the positive multiple reaction monitoring (MRM) mode and the negative single ion monitoring (SIM) mode, respectively. The analytes were separated using gradient elution on C8 or phenyl column. Satisfactory results pertaining to selectivity, linearity, matrix effect, accuracy and precision, recovery, stability, dilution integrity, carryover, and incurred sample analysis (ISR) were obtained. The calibration ranges in human plasma were as follows: 0.00200–1.00 μg/mL for C16 DP‐VPA, 0.0100–5.00 μg/mL for C18 DP‐VPA, and 0.0500–20.0 μg/mL for VPA. The linear ranges in urine and fecal homogenate were 0.00500–2.00 μg/mL and 0.00200–0.800 μg/mL for C16 DP‐VPA, 0.00500–2.00 μg/mL and 0.0100–4.00 μg/mL for C18 DP‐VPA, and 0.200–80.0 μg/mL for VPA, respectively. The intra‐ and inter‐batch coefficients of variation in three matrices ranged from 1.7% to 12.4% while the accuracy values ranged from 85.4% to 111.7%. The developed methods were successfully applied to determine pharmacokinetics of DP‐VPA tablet after a single oral dose of 1200 mg in 12 healthy Chinese subjects under fed condition.
关键词： UPLC–MS/MS,pharmacokinetics,excretion,epilepsy,DP‐VPA
更新于2025-09-11 14:15:04